Trellis Bioscience is a therapeutic antibody company developing treatments for infectious diseases and oncology indications.
Trellis Bioscience develops a technology platform for cellular informatics. The company's technology has applications in the discovery and production of therapeutic monoclonal antibodies. Its cell biology platform provides a direct readout at the single cell level for monitoring activity of diverse cell types and quantifying the impact of potential therapeutic interventions. The company is based in San Francisco, California.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Oct 1, 2019 | Grant | $3.20M | 1 | CARB-X | — | Detail |
Nov 9, 2011 | Debt Financing | $235K | — | — | — | Detail |
Aug 7, 2009 | Series Unknown | $11.71M | — | — | — | Detail |
Feb 14, 2007 | Series B | $10M | 4 | Novartis Venture Fund | — | Detail |
Jan 2, 2004 | Series A | $3.42M | — | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
CARB-X | Yes | Grant |
Novartis Venture Fund | Yes | Series B |
Easton Capital | — | Series B |
Morgenthaler Ventures | — | Series B |
Pac-Link | — | Series B |